Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Affymax® Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide™ Regardless of Patient Baseline Renal Function
June 12th, 2009
Affymax, Inc. (Nasdaq:AFFY) announced data from a post hoc analysis of 120 patients in a Phase 2 clinical trial of Hematide™ in non-dialysis chronic kidney disease (CKD) patients. The data suggest that there is no major impact of baseline renal function as measured by Estimated Glomerular Filtration Rate (eGFR) on the monthly Hematide dose required to increase and maintain hemoglobin (Hgb) values within target range in non-dialysis CKD patients. The data were presented by Iain C. Macdougall, M.D. at the World Congress of Nephrology meeting being held in Milan, Italy. “As Hematide is partially excreted by the kidneys, it was imperative to evaluate whether renal function...
Source: Health Business Week (2009-06-12)
|
